Even though the FDA's Oncologic Drugs Advisory Committee (ODAC) in June declined to back approval of AstraZeneca's Lynparza (olaparib), an oral inhibitor of polyadenosine 5-diphosphoribose polymerases, in ovarian cancer, the agency defied that advice and granted its blessing anyway on 19 December – although for a slightly different indication.
Shares of AstraZeneca closed at $71.69, down 42 cents.


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

